InterVenn Biosciences makes Malaysia its regional hub

The company CEO wanted to be close by with the experts and patients in the region who are besieged by the disease

by AUFA MARDHIAH / pic credit intervenn.com

US-BASED clinical technology company, InterVenn® Biosciences made Malaysia its regional hub for delivery of its medical healthcare services and products across Asean and Asia-Pacific regions.

InterVenn has acquired a new 13,000 sq ft (1,207.74 sq m) office and laboratory equipped with state-of-the-art equipment, located in Technology Park Malaysia, Kuala Lumpur. The facility provides an opportunity to tap into and develop locally-based biomedical talent in Malaysia. The lab is also the only InterVenn lab located outside the US.

InterVenn co-founder and CEO Aldo Carrascoso (right) said the main decision in choosing Malaysia as a regional hub is because he wanted to be close by with the experts and patients in the region who were besieged by the disease — in line with his mission that no one should ever be blindsided by the disease.

“Here at InterVenn, maladies are holistically understood, adequately controlled and even manipulated to benefit all. We exist today to revisit the health-disease spectrum with an unprecedented and exclusive focus on “glyco” while incorporating the latest technological advancements and fully supporting our Malaysian office with those tools,” he said in a statement today.

Meanwhile, InterVenn Malaysia’s GM Fadzhairi Jabar said a part of this growth was a result of the support of regional collaborators and partners, as well as recognition given by the relevant government agency and research institutions.

“Last year, InterVenn was certified as part of the Bioeconomy Corp’s BBA programme — expanding and fostering this interaction in line with our vision towards creating a world where everyone in the region benefits from our goals,” he added.

In addition, InterVenn has developed a first-of-its-kind glycoproteomics-based liquid biopsy solution by utilising artificial intelligence (AI) to detect and diagnose cancers — which enables researchers at academic centres and biopharmaceutical companies to assess post-translational modifications at an unprecedented scale and speed.

Currently, the company has various breakthrough tests for various types of cancer and diseases in the pipeline. Furthermore, InterVenn’s non-traditional approach to epi-proteomics is a combination of mass spectrometry and AI/Machine Learning (AI/ML).

On the company’s expansion, recently InterVenn expanded to San Diego, Southern California to enhance its commercial and support teams in serving and benefitting the thriving life sciences community; while the expansion in Australia allows the company to grow the scientific collaboration with talent in ML/AI and informatics to have wider access to clinical samples and biobanking.